AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1830860
Drug: Nicotinamide (oral)
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide (oral)
Trial: 6228933
Drug: Hydergine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydergine treatment
Trial: 15213636
Drug: Gacyclidine 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gacyclidine 0.02 mg/kg
Trial: 15213636
Drug: Gacyclidine 0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gacyclidine 0.005 mg/kg
Trial: 15213636
Drug: Gacyclidine 0.001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gacyclidine 0.001 mg/kg
Trial: 2664089
Drug: Levodopa (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (mean dose 444 mg daily)
Trial: 2664089
Drug: Bromocriptine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (mean dose 50 mg daily)
Trial: 918999
Drug: Chemotherapy prior
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy prior to radiotherapy
Trial: 918999
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with a focal dose of 3000 rd within three weeks
Trial: 29156619
Drug: Calorie-dense and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie-dense and protein-rich early enteral nutrition (1300 Kcal/L and 66.7 g/L protein)
Trial: 29156619
Drug: Standard isocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard isocaloric early enteral nutrition (1000 Kcal/L and 38 g/L protein)
Trial: 25907158
Drug: Idebenone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone (300 mg three times a day)
Trial: 19242030
Drug: Tepid sponging
RxNorm normalized name: spongia tosta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepid sponging and antipyretic drug (Paracetamol) (n=73)
Trial: 19242030
Drug: Only antipyretic
RxNorm normalized name: ANTIPYRETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only antipyretic drug (Paracetamol) (n=77)
Trial: 11717609
Drug: Culture-guided antibiotics
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture-guided antibiotics for treatment
Trial: 30839402
Drug: Huperzine-A treatment
RxNorm normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine-A treatment for 8 weeks
Trial: 26179113
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (3 g/day) with low-calorie diet
Trial: 26179113
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g/day) with low-calorie diet
Trial: 23388213
Drug: Active cardiac
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active cardiac resynchronization therapy
Trial: 23388213
Drug: Inactive cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive cardiac resynchronization therapy
Trial: 19339233
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg meloxicam (formulation 1)
Trial: 19339233
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg meloxicam (formulation 2)
Trial: 22795204
Drug: ABT-089 40
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-089 40 mg once daily
Trial: 22795204
Drug: ABT-089 80
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-089 80 mg once daily
Trial: 12447010
Drug: Didanosine EC
RxNorm normalized name: didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine EC (400 mg once daily), Stavudine (40 mg twice daily), Nelfinavir (750 mg three times daily)
Trial: 12447010
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg twice daily) plus Lamivudine (150 mg twice daily) and Nelfinavir (750 mg three times daily)
Trial: 7638372
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 50 micrograms twice daily
Trial: 7638372
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 20 mg four times daily
Trial: 2797637
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (50-100 micrograms every hour)
Trial: 2797637
Drug: Meperidine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (25-50 mg every 2-3 hours)
Trial: 23983082
Drug: NURTURE intervention
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NURTURE intervention (weekly for 16 sessions, 1.5 hours each)
Trial: 22380529
Drug: LAR 30
RxNorm normalized name: Signifor LAR 30 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAR 30 mg
Trial: 22380529
Drug: LAR 10
RxNorm normalized name: Tubigrip Tubular 10m Roll
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAR 10 mg
Trial: 22380529
Drug: LAR 30
RxNorm normalized name: Signifor LAR 30 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAR 30 mg, LAR 10 mg, Saline (Control)
Trial: 15023167
Drug: Tenatoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenatoprazole 40 mg (T40)
Trial: 15023167
Drug: Tenatoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenatoprazole 20 mg (T20)
Trial: 15023167
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg (E40)
Trial: 9583368
Drug: Glutamine-supplemented TPN
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-supplemented TPN (0.22 g glutamine x kg(‐1) x d(‐1) as glycyl‐glutamine)
Trial: 21622587
Drug: Indacaterol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 150 μg q.d.
Trial: 21622587
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 μg q.d.
Trial: 18655566
Drug: E-leng Capsule
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E-leng Capsule (ELC) administered before and after operation for 3 months starting from the 7th day post-operation
Trial: 18655566
Drug: Danazol administered
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol administered from the 7th day post-operation for 3 months (Control group)
Trial: 18655566
Drug: E-leng Capsule
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E-leng Capsule (ELC)
Trial: 16959188
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine 4 mL with 20 microg epinephrine
Trial: 16959188
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine 4 mL with 40 microg epinephrine
Trial: 16959188
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine 4 mL with 0 microg epinephrine
Trial: 10690160
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g sucrose (859 kJ)
Trial: 10690160
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g maize oil (1569 kJ)
Trial: 10690160
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g sucrose, 20 g maize oil (1213 kJ)
Trial: 1773870
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 in solid gel (Cerviprost)
Trial: 1773870
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 in liquid cellulose-gel
Trial: 31090511
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg SHIP1 activator
Trial: 31090511
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg SHIP1 activator
Trial: 21206277
Drug: Sub-Tenon lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sub-Tenon lidocaine injection (2% lidocaine)
Trial: 21206277
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection (1 ml)
Trial: 11788013
Drug: Pergolide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide therapy
Trial: 16353581
Drug: Clomipramine (CMI)
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine (CMI) 12.5 mg
Trial: 3356082
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (325 mg) with methyldopa (500 mg)
Trial: 3356082
Drug: Ferrous gluconate
RxNorm normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous gluconate (600 mg) with methyldopa (500 mg)
Trial: 3356082
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (325 mg) in hypertensive subjects
Trial: 27752170
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg/(kg×h))
Trial: 24117597
Drug: Lixisenatide one-step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lixisenatide one-step dose increase
Trial: 24117597
Drug: Lixisenatide two-step
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lixisenatide two-step dose increase
Trial: 20308907
Drug: Propofol 200
RxNorm normalized name: propofol 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 200 mg
Trial: 20308907
Drug: Propofol 350
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 350 mg
Trial: 9864711
Drug: Pimozide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide (1 mg daily for 3-12 months)
Trial: 6958187
Drug: Behavioural change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural change treatment programme (Section II)
Trial: 6958187
Drug: Cardiologist-led treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiologist-led treatment programme (Section I)
Trial: 21739158
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 2/3 of I.V. predicted carboplatin dose by I.V. infusion and the rest 1/3 as aerosol (jet nebulised D1)
Trial: 21739158
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: I.V. chemotherapy (carboplatin AUC ≈ 5.5 D1)
Trial: 15240584
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment (0.074 mg/kg, sc three times per week)
Trial: 12191749
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy (60% inhaled oxygen)
Trial: 9707845
Drug: KOH preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOH preparation
Trial: 9707845
Drug: KOH preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOH preparation and CFW
Trial: 407963
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition with a high calorie and nitrogen content (group A)
Trial: 407963
Drug: Intravenous dextrose/saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dextrose/saline solution (group B)
Trial: 31271193
Drug: Phenylalanine intake
RxNorm normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylalanine intake ranging from 7.20 to 40.0 mg .kg‐1 .d‐1
Trial: 31271193
Drug: Adaptation to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptation to a milkshake diet providing protein at 1.0 g.kg‐1 .d‐1 and energy at 1.7 × REE for two days prior to study
Trial: 31271193
Drug: Direct amino
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct amino acid oxidation method measuring oxidation of l‐[1‐13C]phenylalanine to 13CO2
Trial: 25993119
Drug: Anifrolumab (anti-IFNAR1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anifrolumab (anti-IFNAR1 receptor antibody)
Trial: 24925440
Drug: Voriconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (400 mg every 12 h on day 1, then 300 mg every 12 h for 27.5 days)
Trial: 19317630
Drug: Other antidepressants
RxNorm normalized name: Other antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antidepressants (citalopram, duloxetine, fluoxetine, paroxetine, sertraline, venlafaxine)
Trial: 12365828
Drug: Intra-arterial thrombolysis
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial thrombolysis with other agents
Trial: 8545790
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Split course radiotherapy (1.8 to 2 Gy single dose) over 10 weeks with chemotherapy (5‐FU, methotrexate, cyclophosphamide)
Trial: 8545790
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Conventional radiotherapy (1.8 to 2 Gy single dose) over 6 weeks with chemotherapy (5‐FU, mitomycin C)
Trial: 30878323
Drug: Probiotics (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (daily capsules containing Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12)
Trial: 27634419
Drug: NGF injection
RxNorm normalized name: Panthenol 1 g in 100 mL TOPICAL SOLUTION [NGF 574H HAIR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGF injection in infrapatellar fat pad (IFP) followed by acid infusion (5 mL of phosphate-buffered acidic saline at 20 mL/h)
Trial: 27634419
Drug: NGF injection
RxNorm normalized name: Panthenol 1 g in 100 mL TOPICAL SOLUTION [NGF 574H HAIR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGF injection in tibialis anterior (TA) muscle followed by acid infusion (10 mL at 30 mL/h)
Trial: 27634419
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection in infrapatellar fat pad (IFP) followed by acid infusion (5 mL of phosphate-buffered acidic saline at 20 mL/h)
Trial: 27634419
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection in tibialis anterior (TA) muscle followed by acid infusion (10 mL at 30 mL/h)
Trial: 25843816
Drug: Submucosal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Submucosal dexamethasone 8 mg
Trial: 24716610
Drug: Intravenous KGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous KGF (60 μg/kg) for 3 days
Trial: 24716610
Drug: Inhibition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition of GM-CSF receptor activation
Trial: 15450725
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment time of radiotherapy reduced to 5.5 weeks, 6.5 weeks, and 9.5 weeks with a total dose of 66-68 Gy, 2 Gy/fx.
Trial: 9746769
Drug: D-FISH technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-FISH technique for monitoring therapy in CML
Trial: 7911136
Drug: 250-micrograms bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250-micrograms bolus injection of somatostatin + 250 micrograms/h slow infusion
Trial: 7911136
Drug: 500-micrograms bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-micrograms bolus injection of somatostatin + 250 micrograms/h slow infusion
Trial: 3295548
Drug: Control (therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (therapy without photocoagulation)
Trial: 29405252
Drug: Standard follow-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard follow-up (measurement of calcium and parathyroid hormone on postoperative day 1 and systematic supplementation with calcium and vitamin D; control group)
Trial: 12085976
Drug: Aprotinin (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (280 mg in pump prime)
Trial: 8465822
Drug: Glucose-polymer solution
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-polymer solution
Trial: 3079994
Drug: Branched chain‐enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain‐enriched amino acid solutions (valine-enriched)
Trial: 3079994
Drug: Branched chain‐enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain‐enriched amino acid solutions (leucine-enriched)
Trial: 30336598
Drug: Iron Treatment
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron Treatment Group (ITG) - 325mg/d of ferrous sulphate for 11 weeks
Trial: 30336598
Drug: Iron Treatment
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron Treatment Group (ITG)
Trial: 23528388
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (5 days/week, 2 sessions/day for 21 days, 15 min/session)
Trial: 23528388
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation program without mirror therapy
Trial: 21627403
Drug: High-dose parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose parenteral polyoestradiol phosphate (PEP) 240 mg i.m. twice a month for 2 months and thereafter monthly
Trial: 21627403
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen deprivation (CAD) with flutamide (Eulexin®) 250 mg per os three times daily and triptorelin (Decapeptyl®) 3.75 mg i.m. per month or bilateral orchidectomy
Trial: 18757238
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day
Trial: 18757238
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg clopidogrel once a day
Trial: 18757238
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg telmisartan once per day
Trial: 12908135
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation strategies
Trial: 12908135
Drug: Platinum and
RxNorm normalized name: Platinum and/or platinum compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum and 5-fluorouracil drug combinations
Trial: 12908135
Drug: New biologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New biologic agents in combined modality treatment schemes
Trial: 11127445
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of enalapril (mean dose achieved 17.9 mg/day)
Trial: 11127445
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of enalapril (mean dose achieved 42 mg/day)
Trial: 2154428
Drug: Azithromycin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (three regimens including a single oral dose)
Trial: 2154428
Drug: Doxycycline (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (standard treatment)
Trial: 26218852
Drug: Cortisol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (20 mg, single oral dose)
Trial: 23727103
Drug: Midazolam (Mi)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (Mi) + Morphine (Mo)
Trial: 23727103
Drug: Morphine (Mo)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (Mo) alone
Trial: 20049561
Drug: Palonosetron (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.25 mg i.v.)
Trial: 20049561
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg i.v.)
Trial: 19288149
Drug: Sea buckthorn
RxNorm normalized name: sea buckthorn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sea buckthorn berries (SBB), 28 g daily for 3 months
Trial: 15599835
Drug: Milrinone infusion
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone infusion for 48 to 72 hours
Trial: 15599835
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 48 to 72 hours
Trial: 9300324
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amlodipine and hydrochlorothiazide